Your browser doesn't support javascript.
loading
Pharmacogenetic guidelines and decision support tools for depression treatment: application to late-life.
Chang, Donald D; Eyreeuro, Harris A; Abbott, Ryan; Coudreaut, Michael; Baune, Bernhard T; Shaman, Jeffrey A; Lavretsky, Helen; Lenze, Eric J; Merrill, David A; Singh, Ajeet B; Mulsant, Benoit H; Reynolds, Charles F; Müller, Daniel J; Bousman, Chad.
Afiliación
  • Chang DD; School of Medicine, University of Queensland-Ochsner Clinical School, Brisbane, Queensland, 4072, Australia.
  • Eyreeuro HA; Innovation Institute, Texas Medical Center, Houston, TX 77006, USA.
  • Abbott R; IMPACT SRC, School of Medicine, Deakin University, Geelong, Victoria, 3220, Australia.
  • Coudreaut M; Department of Psychiatry, University of Melbourne, Melbourne, Victoria, 3003, Australia.
  • Baune BT; Discipline of Psychiatry, University of Adelaide, Adelaide, South Australia, 5055, Australia.
  • Shaman JA; University of Surrey, Surrey, GU2 7XH, UK.
  • Lavretsky H; David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA.
  • Lenze EJ; Department of Psychiatry, Intermountain Healthcare, Salt Lake City, UT 84102, USA.
  • Merrill DA; Discipline of Psychiatry, University of Adelaide, Adelaide, South Australia, 5055, Australia.
  • Singh AB; Coriell Life Sciences, Philadelphia, PA 19112, USA.
  • Mulsant BH; David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA.
  • Reynolds CF; Department of Psychiatry, Washington University, St Louis, MO 63130, USA.
  • Müller DJ; David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA.
  • Bousman C; IMPACT SRC, School of Medicine, Deakin University, Geelong, Victoria, 3220, Australia.
Pharmacogenomics ; 19(16): 1269-1284, 2018 11.
Article en En | MEDLINE | ID: mdl-30422065
ABSTRACT
Late-life depression (LLD) is a major depressive disorder that affects someone after the age of 60 years. LLD is frequently associated with inadequate response and remission from antidepressants, in addition to polypharmacy. Pharmacogenetics offers a promising approach to improve clinical outcomes in LLD via new discoveries determining the genetic basis of response rates and side effects, as well as the development of tailored pharmacogenetic-based decision support tools. This invited review evaluates the LLD pharmacogenetic evidence base and the extent to which this was incorporated into existing commercial decision support tools and clinical pharmacogenetic guidelines.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Farmacogenética / Depresión / Trastorno Depresivo Mayor / Antidepresivos Tipo de estudio: Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: Pharmacogenomics Asunto de la revista: FARMACOLOGIA / GENETICA MEDICA Año: 2018 Tipo del documento: Article País de afiliación: Australia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Farmacogenética / Depresión / Trastorno Depresivo Mayor / Antidepresivos Tipo de estudio: Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: Pharmacogenomics Asunto de la revista: FARMACOLOGIA / GENETICA MEDICA Año: 2018 Tipo del documento: Article País de afiliación: Australia